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Aims and objectives
- API’s with acicular habits are commonplace and present 
processing and handling challenges due to poor flow. This 
is traditionally addressed by wet granulation processes 
during formulation. Currently continuous direct 
compression (CDC) is gaining favour as a simplified 
formulation and dose formation process. However, poor 
flow properties limit CDC. This work aims to enable CDC 
by spherical agglomeration in the primary process and 
develop underpinning modelling approaches to allow 
formulations to be explored in-silico (i.e. digital twin)
- Here at CMAC an integrated crystalisation-spherical 
agglomeration-drying-blending-compression process is 
being developed (microfactory) to be used to parameterise 
and develop modelling tools on the g-formulate package 
- This work presents some of the activities on the 
compression component to parameterise and develop a 
suitable model to enable the process to be explored (i.e. 
digital twin) 
Modelling – predictive experimental outcomes (Fig. 2)
- Model fitted reasonably well for single components 
- Over-prediction for the binary mixtures: volumetric mixing rules 
insufficient for complex solid behaviour
- Tablets with a tensile strength > 1.7 MPa are within the 99% 
confidence interval (    , Fig.2B)
Digital twin
The gFormulate model was parameterised with pure 
component (Fig. 1) and binary mixtures (Fig. 2) compression 
data of in terms of tablet tensile strength in the absence of 
porosity (T0), bonding capacity (k) and compressibility 
constant (K) of the Gavi and Reynolds model (2014).
Next steps
Stretch cryst-SA process to provide range of input materials and develop 
methods to predict model parameters with materials properties 
Use pure component parameters to design and optimise targeted experiment 
to validate model, benchmark and develop digital twin approach
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Fig. 1: A) Single component and B) binary mixtures (Pharmatose 50M/Avicel PH-101) compression data.
Fig. 2: Predictive experimental outcomes.
Performance test
Formulated, commercial product releases fastest. Spherical 
agglomerates release slower than raw material Lovastatin in 20 mg 
tablets (70% Lactose, 30% Avicel PH-101).
1A 1B
2A
2BTensile strength T = T0e
-kεtablet
ε tablet = 1 – RD tablet
Relative density RD tablet = RD initial (
𝑃
106
)
1
𝑲
Volumetric mixing rules
i
i
iTmixT  = ,0,0
i
i
ibmixb kk = ,,
i
i
iTmixT KK = ,,
17.6
32.1
45.7
57.7
44.8
66.4
78.0
86.7
76.6
90.6
96.4 98.9
0
20
40
60
80
100
120
0 10 20 30 40 50
%
 L
O
V
 r
el
ea
se
d
 (
2
0
m
g
 d
o
se
)
time (mins)
Spherical Agglomerates
Molekula raw material
LOV ratiopharm
Gavi E., and Reynolds G.K., (2014). System model of a tablet manufacturing process. Comput. Chem. Eng. 71, 130-140. 
Leane M., Pitt K., Reynolds G., and Manufacturing Classificstion System Group (2015). A proposal for a drug product 
Manufacturing Classification System (MCS) for oral solid dosage forms. Pharm. Dev. Technol. 20, 12-21.
Fig. 3: Product 
performance test 
Lovastatin commercial 
product, raw material 
and spherical 
agglomerates.
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PPA 1 – crystal engineering coupled with polymer processing
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Activities - HME – 3D printing process stream 
Polymer-Drug Phase EquilibriaTailoring Drug release profile by 3D design of dosage form
FDM 3D printing filament development
Mechanical properties printing process
New process platform
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In-vitro drug release profile of 10 and 50 % drug loaded 3DP tablets. 
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Mechanical properties - FDM filaments
3DP tablet shapes: 
SC – solid cylinder, SLGC – slotted grid 
with cap, SLG – slotted grid, SLGE –
slotted grid extended
Volume
(mm3)
Total 
surface 
area
(mm2)
Outside
Surface
Area
(mm2)
Surface Area 
/ Volume
(mm2/mm3)
SC 157.6 189.6 189.6 1.2
SLGC 160.2 472.0 239.2 1.5
SLG 160.2 391.0 391.0 2.4
SLGE 155.3 515.1 515.1 3.3
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